FDA Accepts Tab cel BLA Resubmission

Company Atara Biotherapeutics; Pierre Fabre Event Type Regulatory (BLA Class 2 Resubmission Accepted) Modality Allogeneic EBV-specific T-cell therapy Asset Tabelecleucel (tab-cel; Ebvallo in Europe) Target EBV-infected cells Disease Area EBV-positive post-transplant lymphoproliferative disease (PTLD) Summary FDA accepted Pierre Fabre’s Class 2 resubmission of the tabelecleucel…